New England Journal of Medicine· 2016Q1· Clinical trial
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
- 1,750citations
- Q1SCImago
- 2016year
Short summary
Romosozumab significantly reduced the risk of new vertebral fractures by 73% at 12 months and 75% at 24 months in postmenopausal women with osteoporosis compared to placebo.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Orthopedics and Sports Medicine
Orthopedics and Sports MedicineMedicine